UNSPSC 85651322: Removal of nonautologous tissue substitute from upper muscle, percutaneous approach

This classification denotes the group of activities that yields a surgical intervention or procedure to removal of nonautologous tissue substitute from upper muscle, percutaneous approach. This surgical intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 0KPX3KZ

UNSPSC 85651322 Removal of nonautologous tissue substitute from upper muscle, percutaneous approach, is a Commodity code that shows minimal alignment with recent state and local procurement activity. The code describes a specific surgical procedure, yet the six most recent opportunities posted under this code encompass independent medical evaluation services for pension disability determinations, surgical carve-out benefit programs, occupational medical surveillance, emergency and specialty hospital services for detained youth, pharmacy benefit management, and temporary health professional staffing—none of which involve tissue substitute removal or upper muscle procedures. The source material presents no solicitations for the surgical procedure the code nominally describes. State and local governments appear to have tagged these opportunities with this code in error or as a proxy classification, but the actual work being bought bears no relationship to the code's intended scope.

No relevant procurement activity under UNSPSC 85651322 is evident in the recent opportunities block. The issuing bodies include the City of Phoenix Retirement Office, the City of Long Beach, the Washington State Department of Transportation, Harris County Juvenile Probation Department, Collier County Board of County Commissioners, and the County of Santa Clara Health System—spanning Arizona, California, Washington, Texas, and Florida. Given the systematic mismatch between the code's medical definition and the work actually being solicited, this code should not drive pursuit decisions for firms offering surgical services or tissue-substitute removal expertise.